Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has announced the closing of a non-brokered private placement totaling approximately CAD$5 million, providing capital to advance its oncology pipeline. The financing, structured with Sorbie Bornholm LP and Sorbie Investments LLP, involves the issuance of 7.94 million units at a notional price of CAD$0.63 per unit. Each unit consists of one common share and one warrant exercisable at CAD$0.77 for a three-year period.
The proceeds will be made available to the company through an 18-month sharing arrangement tied to the volume-weighted average trading price of its shares, with monthly settlement amounts varying based on market performance. This structure allows Onco-Innovations to access funds gradually while aligning with its stock performance.
Onco-Innovations stated it intends to use the net proceeds to advance development of its ONC010 program, including manufacturing and preclinical activities, support continued development of its SynoGraph platform, and provide working capital for general corporate purposes. The ONC010 program is a key focus, targeting solid tumours through patented technology for which the company holds an exclusive worldwide license.
The closing of this financing comes at a critical time for the company as it seeks to push its oncology candidates toward clinical trials. The SynoGraph platform, still in development, represents a novel approach in cancer research that could differentiate Onco-Innovations in the competitive biotech landscape.
Investors and industry observers will be watching how the company deploys these funds and whether it can achieve key milestones in the coming months. The company’s ability to secure financing from institutional investors like Sorbie suggests confidence in its technology and strategy.
For more details on the press release, visit https://ibn.fm/1Hrlg. Updates regarding ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.
